News and Comments

Onyx (ONXX) Was Right All Along

  Monday, July 26, 2010

In October 2009, Onyx (ONXX) paid $276 million up front to acquire the privately held Proteolix to get to its multiple myeloma drug carfilzomib. It promised $535 million in future payments largely contingent on carfilzomib's approval. As usual, investors did not like Onyx paying money, because investors do not like any company to pay money to develop or acquire state-of-the- art products. When somebody hates something he sees everything in it with pessimism. Onyx put its hands on carfilzomib, which looked very promising for multiple myeloma cases resistant to current treatments. The breakthrough multiple myeloma drugs Velcade (bortezomib) and Revlimid (lenolidamide) could not prevent the cancer from recurring and failed to work at all on a large percentage of recurrent cancer.  More...


Recent Postings


Archive


Tags

Pluristem (PSTI) Incyte (INCY) Dynavax (DVAX) RenenxBio (RGNX) Ziofpharm (ZIOP) Telaprevir Biogen Idec (BIIB) Rapamune VANDA (VNDA) HALOZYME (HALO) Illumina (ILMN) Agenus (AGEN Alder Biopharmaceuticals (ALDR) ABBVIE (ABBV) Auspex (ASPX) Spike Therapeutics (ONCE) Idenix (IDIX) Intercept (ICPT) Theravance (THRX) Adaptimmune (ADAP) CompuGen (CGEN) Micromet (MITI) Genentech Regeneron (REGN) KITE (KITE) Roche (RHHBY) Array Pharmaceuticals (ARRY) Sequenom (SQNM) Seattle Genetics (SGEN) Alnylam (ALNY) Human Longevity (HLI) Gilead (GILD) GUARDIAN HEALTH Bristol-Myers Squibb (BMY) Aimmune Therapeutics (AIMT) Intermune (ITMN) Onyx (ONXX) TOKAI (TKAOI) Anadys (ANDS) Multiple Myeloma Herceptin Ionis (IONS) Endometrial Cancer Ariad (ARIA) Advaxis (ADXS) Global Cell Therapeutics (GBT) Valeant Pharmaceuticals International (VRX) AstraZeneca (AZN) SUNESIS PHARMACEUTICALS (SNSS) SERES THERAPEUTICS (MCRB) Cytokinetics (CYTK) Human Genome Sciences (HGSI) AERIE PHARMACEUTICALS Sanofi (SNY) Vertex (VRTX) ImmunoGen (IMGN) Elan (ELN) KERYX (KERX) galapagos (GLPG) GlaxoSmithKline (GSK) NANTKWEST (NK) Ridaforolimus Tysabri ACADIA (ACAD) Anacor (ANAC) Intrexon (XON) JUNO (JUNO) ZALTRAP™ ARGOS (ARGS) Exelixis (EXEL) SYNTA (SNTA) OSI (OSIP) Mirati Therapeutics (MRTX) Vitae Pharmaceuticals (VTAE) Zerenex Editas (EDIT) Abbott Laboratories (ABT) Prosensa (RNA) Inovio (INO) Bellicum (BLCM) Dendreon (DNDN) C4 Therapeutics MODERNA ADVENTRIX (ANX) INNOVIVA (INVA) Xoma (XOMA) NEKTAR (NKTR)) Agenus (AGEN) Sanofi (SNA) Biocryst (BCRX) Sangamo (SGMO) Trastuzumab-DM1 Sarepta (SRPT) IDERA (IDRA) Jazz Pharmaceuticals (JAZZ) BIOMARIN (BMRN) Galena (GALE) REGULUS (RGLS) Sanofi-Aventis (SAN) Prolor Biotech (PBTH) NOVOCURE (NVCR) ISIS (ISIS) Roche (ROCHE) Velcade (bortezomib) Revlimid (lenolidamide) Amgen (AMGN) Benlysta (belimumab) Merck (MRK) ARCA (ABIO) AGOS (ARGS) PTC Therapeutics (PTCT) Theravance Bio Pharma (TBPH)